Growth Metrics

Summit Therapeutics (SMMT) Change in Cash (2016 - 2026)

Summit Therapeutics filings provide 13 years of Change in Cash readings, the most recent being -$118.8 million for Q1 2026.

  • Quarterly Change in Cash fell 211.34% to -$118.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$105.0 million through Mar 2026, down 169.9% year-over-year, with the annual reading at $120.4 million for FY2025, 256.6% up from the prior year.
  • Change in Cash hit -$118.8 million in Q1 2026 for Summit Therapeutics, down from -$13.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $526.6 million in Q4 2022 and bottomed at -$577.6 million in Q1 2023.
  • Average Change in Cash over 5 years is $2.1 million, with a median of -$9.8 million recorded in 2024.
  • The largest annual shift saw Change in Cash surged 6327.22% in 2022 before it crashed 10307.42% in 2023.
  • Summit Therapeutics' Change in Cash stood at $526.6 million in 2022, then crashed by 90.96% to $47.6 million in 2023, then tumbled by 76.72% to $11.1 million in 2024, then tumbled by 219.88% to -$13.3 million in 2025, then crashed by 793.33% to -$118.8 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Change in Cash are -$118.8 million (Q1 2026), -$13.3 million (Q4 2025), and -$59.3 million (Q3 2025).